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ABSTRACT 
 
The development of robust non-viral vectors could facilitate clinical gene therapy 
applications and may overcome some of the immune complications of viral vectors.  
Nevertheless, most non-viral gene deliver approaches typically yield only transient 
and/or low gene expression. To address these caveats, we have explored piggyBac 
transposons to correct hemophilia B by liver-directed factor IX (FIX) gene therapy in 
hemophilic mice. To achieve this, we combined the use of: (i) a hyperactive codon-
optimized piggyBac transposase, (ii) a computationally enhanced liver-specific 
promoter, (iii) a hyper-functional codon-optimized FIX transgene (FIX R338L Padua) 
and (iv) a modification of the transposon terminal repeats. This combination strategy 
resulted in a robust 400-fold improvement in vector performance in hepatocytes 
yielding stable supra-physiological human FIX activity (>1 year). Liver-specific 
expression resulted in the induction of FIX-specific immune tolerance. Remarkably, 
only very low transposon/transposase doses were required to cure the bleeding 
diathesis. Similarly, PB transposons could be used to express supra-physiologic factor 
VIII levels using low transposon/transposase doses. PB transposition did not induce 
tumors in a sensitive hepatocellular carcinoma-prone mouse model. These results 
underscore the potency and relative safety of the latest generation PB transposons, 
which constitutes a versatile platform for stable and robust secretion of therapeutic 
proteins. 
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INTRODUCTION 
 
Clinical evidence demonstrates that gene therapy is effective to treat patients suffering 
from a wide range of hereditary diseases. This could be attributed largely to the 
improvement in viral vector-based gene transfer technologies. Despite these 
encouraging results, viral vectors can be inactivated by pre-existing neutralizing 
antibodies that preclude gene transfer.1 This is compounded by the induction of 
cytotoxic T-cell responses directed against the gene-modified cells, consequently 
preventing long-term gene expression. Moreover, manufacturing of clinical-grade 
viral vectors is challenging and their restricted cargo capacity can hamper clinical 
translation. Non-viral gene transfer may overcome some of these limitations and offer 
some advantages, especially considering the capacity to accommodate larger inserts, 
the lack of pre-existing host immunity, and reduced costs and time for the production 
of clinical-grade non-viral DNA plasmid-based vectors. Nevertheless, they typically 
do not stably integrate into the genome, and consequently yield only transient 
expression of the gene of interest.2  We and others have demonstrated that this could 
be overcome by using DNA transposons that stably integrate their therapeutic cargo 
into the target cell genome, enabling stable expression of the gene of interest.3, 4 The 
piggyBac (PB) transposon system, originally derived from the cabbage looper moth 
Trichoplusia ni 5,  is among the most promising transposons for gene therapy 
applications. To convert PB transposon into a gene delivery tool, a binary system is 
required that is composed of an expression plasmid that encodes the PB transposase 
and a donor plasmid containing the gene of interest, which is flanked in cis by the 
transposon terminal repeat sequences required for transposition. PB transposons can 
efficiently transpose in mammalian cells 6, 7 and can deliver large transgenes 8, which 
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cannot be readily accommodated into most viral vectors due to their intrinsic 
packaging constraints. PB has been efficiently applied as a tool for functional 
genomic studies, ex vivo genetic modification of somatic and embryonic cells and 
generation of induced pluripotent stem cells.9, 10 However, there are only few studies 
that focus on direct in vivo gene transfer with PB and most of these relied on reporter 
genes.11-15 In the present study, we explored the use of PB transposons for liver-
directed gene therapy of hemophilia B, which has not yet been investigated.  
Hemophilia B is a hereditary bleeding disorder caused by a defective factor IX (FIX) 
gene. It is currently treated by repeated clotting factor infusions but this treatment is 
not curative.16 Moreover, some patients develop neutralizing antibodies against the 
administered recombinant FIX protein that renders the therapy ineffective and 
bleeding episodes difficult to manage. Hence, hemophilia B is an attractive target 
disease to validate PB transposon-based gene therapy approaches, which has 
implications for other hereditary disorders 3, including liver-borne diseases. The main 
objective of our present study therefore consisted of establishing proof-of-concept 
that PB transposons encoding FIX can be used for liver-directed gene delivery cure 
hemophilia B and to assess their overall efficacy and safety in appropriate mouse 
models.  Maximizing the therapeutic index of a given gene transfer vector is a crucial 
step towards implementation of successful clinical trials. Hence, we wanted to 
augment the efficiency of transposon-mediated gene therapy using a multi-layered 
strategy by optimizing each one of its components including the PB transposase and 
the transposon, the liver-specific promoter used to drive FIX and the FIX transgene 
itself. Our results demonstrated that PB transposons in conjunction with a mouse 
codon-optimized PB transposase (mPB) resulted in prolonged FIX expression and 
cure hemophilia B in FIX-deficient mice, which had not been shown previously. 
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Moreover, we showed that the efficiency of PB-mediated gene therapy could be 
enhanced by using the latest generation hyperactive PB transposase (hyPB) and by 
modifying the transposon terminal repeats.17-19 In addition, the use of a liver-specific 
promoter coupled to in silico designed cis-regulatory modules  (CRMs) further 
increased FIX expression levels.20-22 Finally, we demonstrated that the overall 
efficacy could be further increased by using a codon-optimized FIX containing a 
hyper-functional gain-of-function mutation (i.e. FIX Padua R338L).23, 24This 
combinatorial strategy resulted in robust FIX activity at supra-physiologic levels, 
substantially reducing the vector dose requirement for reaching therapeutic efficacy. 
Moreover, it enabled induction of immune tolerance to FIX and prevented the 
generation of anti-FIX antibodies upon immunization with recombinant FIX. We also 
validated the use of the hyperactive PB platform for delivery of relatively large 
transgenes, such as FVIII. Using a highly sensitive tumor-prone hepatocellular 
carcinoma mouse model, we did not observe any significant increase in oncogenic 
risk upon PB transposition, suggesting that this improved hyperactive PB platform 
has a favorable safety profile.  
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RESULTS 
 
PB provides long-lasting therapeutic hFIX expression levels and phenotypic 
correction in hemophilia B mice 
 
The codon usage optimized transposase (mPB) 25 was evaluated in combination with 
PB-hFIXIA (Fig. 1d) that carried a wild-type hFIX minigene (hFIXIA) 2 and PB-
hFIXco (Fig. 1e) with a codon-optimized hFIX (hFIXco).24, 26, 27 In addition, the PB-
hFIXco transposon contained a small intron upstream of the hFIXco to boost FIX 
expression.2, 26 Both the hFIXIA and hFIXco were driven from a novel and potent 
chimeric liver-specific promoter that contained an in silico designed hepatocyte-
specific cis-regulatory module, designated as HS-CRM8. This element conferred high 
liver-specific expression.20-22 Liver-directed hydrodynamic cotransfection of the PB-
hFIXIA transposon (10 μg) along with 2 μg mPB, resulted in stable therapeutic hFIX 
antigen and activity levels for >12 months in hemophilic FIX-deficient mice (Fig. 
2a). Similarly, liver-directed co-transfection of the PB-hFIXco transposon and mPB 
resulted in a significant ≈12-fold higher (p<0.001) hFIX protein and activity level that 
stabilized in the supra-physiologic range (Fig. 2b). In contrast, hFIX expression and 
activity gradually declined to basal levels in control mice that received either PBS or 
only the transposons in the absence of transposase (Figs. 2a,b). Anti-hFIX antibodies 
could not be detected (data not shown). Transposition is therefore necessary for 
sustained expression. The initial high peak of FIX expression is likely due to the 
presence of non-integrated PB-hFIXIA or PB-hFIXco episomes due to the fact that we 
used an excess amount of transposon plasmid (10 μg). These episomes are gradually 
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lost and are also epigenetically silenced (Fig. 2), consistent with previous 
observations.2, 28, 29  
 
Though the transposon copies per genome content were similar in the liver of animals 
that received equal doses of the PB-hFIXIA or PB-hFIXco transposons (Fig. 2c), we 
observed a significant (p<0.001) increase in hFIX mRNA level for the hFIXco than its 
wild-type counterpart (Fig. 2d). This demonstrated that the optimized expression 
cassette, containing a small intron and a codon-usage optimized hFIX transgene 
(hFIXco), significantly increased mRNA levels concomitant with a robust increase in 
FIX protein expression level. Though codon-optimization may in some cases enhance 
immunogenicity 30, we found no evidence of an increased antibody response to the 
codon-optimized FIX protein. A low level of transposon copies (Fig. 2c) was 
apparent in the absence of any transposase-expressing plasmid 12 months post-
transfection (designated as ‘empty’ – Fig. 1c). Since a relatively high dose of PB 
transposons was used  (10 μg) this likely contributed to the residual presence of 
episomally silenced unintegrated DNA, as shown previously.2, 28, 29  
 
Increased therapeutic efficiency using the hyperactive PB platform 
 
To further improve the efficiency of the PB platform, allowing the use of lower 
transposon/transposase doses, we subsequently explored the use of a hyperactive PB 
(hyPB).17 This hyPB contained  several mutated residues compared to the original 
codon-usage optimized mPB (Figs. 1a,b). Liver-directed hydrodynamic transfection 
of immune deficient SCID mice with 500 ng of PB-hFIXco transposon along with 
1000 ng hyPB resulted in stable supra-physiologic hFIX levels corresponding to 
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200% of normal hFIX levels (Fig. 3a). These FIX levels were significantly higher 
(p<0.001) than what could be achieved with the original mPB transposase. Similarly, 
liver-directed transfection of SCID mice with 50 ng of PB-hFIXco transposon plasmid 
along with 100 ng hyPB resulted in a dose-dependent effect yielding therapeutic hFIX 
levels corresponding to 20% of normal levels. This represented a significant 20-fold 
increase (p<0.001) in FIX levels compared to when the mPB transposase was used 
(Figs. 3a,b).  
 
We next evaluated whether the terminal repeats IRmicro and IRmut16 in combination 
with the hyPB, could further improve the in vivo potency of the PB transposons. A 
significant 1.5-fold increase in hFIX expression was apparent when the IRmicro was 
used compared to IRwt (Figs. 3c,d). Liver-directed transfection in SCID mice of the 
PB-hFIXco/IRmicro (Fig. 1g) transposon (500 ng) along with 1000 ng hyPB 
transposase-encoding plasmid resulted in stable FIX levels reaching approximately 
300% of normal hFIX levels (Fig. 3c).  This represents a 100-fold improvement over 
the 3% FIX activity that could be attained when the hemophilia B were transfected 
with matched doses of PB-hFIXIA and mPB plasmids (Fig. 4c).  Similarly, at 10-fold 
lower PB-hFIXco/IRmicro and hyPB doses a dose-dependent decrease in hFIX 
expression was apparent, yielding 30% of normal hFIX levels.  In contrast, FIX 
expression was not or only slightly increased (Figs. 3e,f) when the IRmut16 was used 
(Fig. 1g) compared to IRwt (Fig. 1e). 
 
 
 
Enhancing PB performance using hyper-functional hFIX-R338L Padua 
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Subsequently, we tested whether the performance of this optimized hyPB and PB-
hFIXco/IRmicro platform could be further enhanced using a synthetic codon-optimized 
FIX transgene harboring a hyper-activating R338L (Padua) mutation.23 We therefore 
constructed a PB-hFIXco-R338L/IRmicro transposon (Fig. 1h) that was co-transfected 
along with a hyPB transposase-encoding construct into hemophilia B mice. Sustained 
FIX antigen levels could be obtained (Fig. 4a, b) with similar expression kinetics as 
in SCID mice (Fig. 3). The hFIXco-R338L transgene exhibited a >6-fold higher 
specific FIX activity with respect to protein levels, yielding up to 1200% FIX activity 
at the highest hFIXco-R338L/IRmicro transposon dose (500 ng).  Most importantly, this 
represents a robust 400-fold improvement over the 3% FIX activity that could be 
attained when the hemophilia B were transfected with matched doses of PB-hFIXIA 
and mPB plasmids (Fig. 4c). Moreover, at the lowest dose of only 50 ng of PB-
hFIXco-R338L/IRmicro transposon and 100 ng hyPB transposase plasmid, supra-
physiological FIX activity could be attained (≈ 200%); whereas matched doses of PB-
hFIXIA and mPB plasmids yielded no detectable FIX activity (Fig. 4c).  
 
Interestingly, none of the hemophilia B mice treated with the PB transposons 
expressing hFIX or hFIX-R338L (Padua) developed an anti-hFIX specific antibody 
response even in the face of immunization with recombinant hFIX protein and 
adjuvant (Fig. 4d). This is consistent with the induction of hFIX-specific immune 
tolerance. Since FIX antigen levels and expression kinetics were similar in 
hemophilia B (Figs. 4a,b) and SCID mice (Figs. 3a-f), this further confirmed the lack 
of hFIX-specific immune responses. 
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The superior potency of the hFIXco-R338L/IRmicro transposon and hyPB transposase 
was confirmed by assessing phenotypic correction 4 months post-transfection in 
hemophilia B mice (Fig. 4e). In particular, hemophilic mice treated with only 50 ng of 
PB-hFIXco-R338L/IRmicro transposon and 100 ng hyPB transposase plasmid achieved 
hemostatic correction and consequently survived the tail-clip assay. In contrast, none 
of the hemophilic mice injected with matched doses of the PB-FIXIA transposon and 
mPB transposase plasmids survived the injury (Fig. 4e).  
  
Transposon copies were similar in the liver of animals that received equal doses of PB 
transposons expressing hFIXco or hFIX-R338L (Padua) in the presence of hyPB (Fig. 
4f) but were significantly higher than in mice injected PB transposons expressing 
hFIXIA in presence of mPB (p<0.01) at both tested doses. Remarkably, hemophilic 
mice treated with only 50 ng of PB-hFIXco-R338L/IRmicro transposon and 100 ng 
hyPB transposase plasmid achieved supra-physiologic hFIX activity (Fig. 4c) and 
rescue of the bleeding phenotype (Fig. 4e). Transposon copies were further reduced  
(< 0.1 copies/diploid genome) decreasing the risk of insertional oncogenesis. 
 
Validating the  hyperactive PB platform for FVIII delivery 
 
We then extended these findings using the codon-optimized B-domain deleted FVIII 
(FVIIIΔBco).31 Liver-directed hydrodynamic transfection of 500 ng of PB-
hFVIIIΔBco/IRmicro transposon along with 1000 ng hyPB in SCID mice resulted in 
stable supra-physiologic hFVIII levels corresponding to 300% of normal hFVIII 
levels (Fig. 4g). Conversely, in the absence of the hyperactive hyPB transposase, 
expression declined gradually to basal levels (Fig. 4g). This confirms that stable 
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genomic integration by transposition is required for stable hepatic FVIII gene 
expression.  These results are consistent with the results obtained with the PB-FIX 
transposons.   
 
Safety assessment in a tumor-prone hepatocellular carcinoma model  
 
To assess the risk of insertional oncogenesis we evaluated the safety profile of the PB 
platform in the DEN-induced HCC mouse model  that resembles human HCC . One 
month after DEN initiation 32 mice were transfected hydrodynamically with either 10 
μg PB-hFIXIA transposon or 500 ng of PB-hFIXco in combination with 2 μg mPB 
plasmid (Fig. 5a). These doses were chosen to obtain similar FIX expression levels 
and compare the intrinsic safety of both PB constructs. The tumor burden was 
assessed 36 weeks post-DEN initiation.  We did not observe any significant 
differences in the number of HCC nodules between mice transfected with PB-hFIXIA 
or PB-hFIXco and mPB and PBS-injected mice (Fig. 5b). In contrast, tumor incidence 
and progression was significantly (p<0.001) increased in control mice that were 
hydrodynamically transfected with a PB-c-Myc transposon (Fig. 5c), (number of 
nodules [>50], max tumor size [>50 mm] compared to PBS-injected mice (number of 
nodules [5,83 ± 1,42], max tumor size [5,70 ± 0,29 mm]. This ultimately resulted in 
significant and accelerated mortality  (i.e. median survival of 157 days) (Fig. 5c), 
consistent with the well established role of c-Myc in liver cancer.33 It is noteworthy 
that a minimal yet significant increase in the number of HCC nodules was apparent in 
DEN-treated control mice that had undergone hydrodynamic transfection (with PBS) 
compared to non-injected DEN-treated mice. This suggests that the hydrodynamic 
procedure per se may provoke tumorigenesis, possibly by triggering a transient liver 
 13
damage and inflammation associated with hepatocyte proliferation 34 (Fig. 5b), 
consistent with previous observations.35 This underscores the high sensitivity of the 
DEN-induced HCC model. 
 
To further rule out that PB transposons contributed to HCC in the DEN-induced 
mouse model, we assessed the PB copy number in normal liver tissue versus HCC 
nodules.  Interestingly, the copy number of the PB-hFIXIA or PB-hFIXco transposons 
was higher in normal liver biopsies compared to the PB copy number in HCC 
nodules. Given the significant decrease in PB-hFIXIA or PB-hFIXco transposon copy 
number in HCC samples, this suggests that HCC initiation and/or progression was not 
associated with stable genomic transposon integration (Fig. 5d). We hereby 
demonstrated that PB transposition in itself does not significantly increase 
tumorigenicity in this sensitive HCC tumor-prone mouse model, which underscores 
the relative safety of the PB-FIX platform. Conversely, the PB-c-Myc copy number 
was significantly increased in HCC nodules versus normal liver biopsies. This 
strongly suggests that c-Myc expression contributed to malignant transformation, 
consistent with natural selection of transformed hepatocyte clones that contained an 
increased number of PB-c-Myc vector copies.  
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DISCUSSION 
 
In this study, we established proof of concept that the PB platform can be used to 
obtain sustained expression (> 1 year) of a therapeutically relevant transgene (i.e. 
FIX) leading to a phenotypic correction of the bleeding diathesis in hemophilia B 
mice. To our knowledge, this is the first report that shows phenotypic correction of a 
genetic disorder using the PB transposon platform with broad implications for the 
field at large. Transposition was necessary to ensure sustained FIX expression and 
stable correction of the bleeding phenotype, whereas FIX expression was transient in 
the absence of the PB transposase. Furthermore, we demonstrated that a robust 400-
fold improvement in vector performance could be achieved using a multi-layered 
approach by using a hyperactive transposase (hyPB), by trimming the transposon 
terminal repeats (IRmicro) and by optimizing the transgene expression cassette itself. 
The expression cassette encoded a codon-optimized FIX or its hyperactive FIX 
R338L (Padua) version that were driven from a robust chimeric liver-specific 
promoter. Consequently, only very low amounts of hyPB and PB transposons were 
needed to achieve supra-physiologic FIX activity levels in hemophilic mice paving 
the way towards pre-clinical large animal studies.   
 
The robust hepatocyte-specific FIX expression levels in the PB transposons could be 
attributed, to the use of the chimeric liver-specific TTR promoter coupled to the in 
silico designed hepatocyte-specific cis-regulatory modules (HS-CRM).20-22 These 
CRMs contained evolutionary conserved clusters of transcription factor binding site 
motifs that conferred high liver-specific gene expression. Moreover, modified vector 
design of the PB-hFIXco and PB-hFIXco-R338L transposons compared to PB-hFIXIA 
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contributed to increased steady-state FIX mRNA levels. The increased activity of 
hFIXco-R338L (Padua) is consistent with our recent studies showing 5-7-fold 
increase FIX activity after liver-directed gene therapy of integration-competent or 
defective lentiviral vectors 24 which was confirmed independently based on adeno-
associated viral vectors.36 
 
The in vivo performance of the PB-FIX transposons and hyPB transposase is 
consistent with previous reports showing sustained expression of reporter genes after 
liver-directed hydrodynamic gene delivery 11-15 and confirm the superiority of the 
hyperactive hyPB compared to the conventional mPB transposase. Moreover, in a 
recent study, PB transposons were shown to stably express a1-antitrypsin (AAT) in 
transfected hepatocytes in vivo.14 Nevertheless, the PB platform had not been 
validated in a disease model and the AAT expression levels attained were modest.  In 
the present study, we also demonstrated that the hyPB platform could be used to 
express supra-physiologic levels of FVIII. The superior activity of the hyPB 
compared to mPB is likely due to the synergistic effect of the point mutations that 
enhance the transposition efficiency by increasing the protein levels and improve the 
mechanism and/or kinetics of transposition.17 The increase in hFIX protein levels 
associated with the use of IRmicro is likely due to increased PB transposition. However, 
an effect at the transcriptional level cannot be excluded.  Trimming the terminal 
repeats may indeed prevent the binding of transcriptional repressors that may 
influence expression of the gene of interest.  This hypothesis is consistent with the 
elevated FIX expression levels in mice transfected with the PB-hFIXco/IRmicro 
transposon in the absence of the hyPB transposase.  
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The FIX and FVIII levels that were attained compared favorably to other non-viral 
gene therapy approaches.37-40 In particular, hydrodynamic transfection of Sleeping 
Beauty-based transposons encoding FIX in conjunction with the early SB11 41 or 
latest SB100X transposase 4 resulted in lower FIX expression levels and required 50 
to100-fold higher doses of SB-FIX transposons (25-50 μg) compared to when the PB-
hFIXco-R338L/IRmicro transposon was used in conjunction with hyPB. This implies 
that the current optimized transposon vectors are least 50 to 100-fold more efficient 
than the state of the art. Alternative methods for non-viral liver-directed gene therapy 
relied on hydrodynamic plasmid or mini-circle delivery but these methods yielded 
lower and/or transient FIX expression.2, 42 The FIX levels that were obtained also 
compare favorably with what can typically be achieved with viral vectors, particularly 
lentiviral and AAV vectors.24, 43-45 
 
The sustained hepatocyte-specific FIX expression in hemophilia B mice was 
consistent with the induction of hFIX-specific immune tolerance, which was 
maintained even upon immunization with hFIX and immune adjuvant. This is 
consistent with the induction of immune tolerance following liver-directed gene 
therapy with AAV or lentiviral vectors when hepatocyte-specific promoters were 
employed, avoiding ectopic expression in antigen-presenting cells.24, 43-45 This 
indicates that the ability to induce FIX-specific immune tolerance is irrespective of 
the vector type and could be attributed to the specific micro-environment in the liver.  
The exact mechanism that accounted for the induction of immune tolerance in the 
liver is not fully understood but possibly involves the induction of 
CD4+CD25+Foxp3+ regulatory T cells. 
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The PB-hFIXIA (Fig. 1d) and PB-hFIXco (Fig .1e) transposons used in the present 
study differ with respect to (i) codon-optimization of the FIX cDNA and (ii) the use of 
a mini-intron from the MVM virus upstream of the FIX cDNA vs. the use of intron A 
of FIX maintained in the natural position in between exons 1 and exon 2 (Fig. 1d). 
The combined effect of these changes resulted in a 10-fold difference in FIX protein 
expression levels (Fig. 2a,d).  We had previously shown that the net effect of FIX 
codon-optimization by itself typically resulted in a 2 to 3-fold increase in FIX protein 
expression.24 This is likely due to an increase in translation initiation.  Consequently, 
the effect of codon-optimization by itself is not sufficient to account for the 10-fold 
difference in FIX protein expression levels. This could be explained by also taking 
into account the increase in steady-state FIX mRNA levels (Fig. 2d). The increase in 
FIX mRNA levels could be due to the effect of the MVM intron. Furthermore, some of 
the nucleotide changes that were introduced in the FIX codons that were intended to 
boost translation may also have inadvertently increased transcription. The increase in 
FIX mRNA did not result in a proportionate increase in FIX protein levels.  This 
suggests that post-transcriptional events may be limiting the control of FIX 
biosynthesis. 
 
 
We subsequently assessed the safety of this PB platform in the highly sensitive DEN-
treated HCC-prone mice. In this model, DEN induces DNA damage, chronic liver 
injury and triggers local and systemic inflammatory reactions followed by 
compensatory hepatocyte proliferation.46 Macroscopic and molecular analysis 
strongly suggests that PB transposition in itself does not enhance the tumorigenic risk.  
As a corollary, it would appear that the HS-CRM8 element does not increase the risk 
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of insertional oncogenesis. Moreover, our stepwise improvements of the PB platform 
required less transposon integrations to obtain sustained therapeutic FIX levels (Table 
1), further reducing the risk of insertional oncogenesis. Indeed, we showed that 
reducing the amount of plasmid used for hydrodynamic gene transfer correlates with a 
reduction in hepatocyte transfection in terms of transposon copy number (Table 1). 
Hydrodynamic transfection typically results in up to 10% of transfected hepatocytes 
in the mouse liver with a preference for the pericentral region of the hepatic acinus.47, 
48 Consequently, this translates to 10-fold the number of integrants per cell that 
actually took up the PB transposons. In particular, a transposon copy number of 0.08± 
0.007 per diploid genome (i.e. following transfection with. 50 ng of PB-hFIXco-
R338L/IRmicro transposon and 100 ng hyPB transposase plasmid) (Table 1, Fig. 4c) 
would correspond to less than one copy per transfected hepatocyte. Such a low copy 
number mjnimizes the risk of insertional oncogenesis. While the level of expressed 
FIX is more relevant than the percent of FIX expressing hepatocytes for correcting the 
bleeding phenotype, it is important to consider that phenotypic correction of other 
diseases may require a significantly greater fraction of gene-modified hepatocytes. 
 
Exhaustive analysis of genomic integration sites of the hyPB platform in transfected 
hepatocytes in vivo will be the subject of future studies. Nevertheless, it is reassuring 
that integration site analyses of transfected human cells revealed previously that PB 
transposons do not favor integration into genes and showed a reduced frequency of 
integrations near transcriptional start sites.14 To augment the specificity of PB 
integration into pre-defined loci, PB transposases were genetically fused to zinc finger 
(ZF) 49, 50 or transcription activator-like effector (TALE) 51 domains specifically 
designed to target specific DNA sequences. However, the overall targeting efficiency 
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was still limiting.  Alternatively, genome engineering approaches based on ZF 
nucleases and CRISPR/Cas9 are currently being explored as alternatives to achieve 
targeted integration in hepatocytes.52, 53 To further increase in vivo targeting 
efficiencies high vector doses are typically required, that are prohibitive for clinical 
translation .52 
 
The first-in-man transposon-based clinical studies have been initiated which further 
underscores its therapeutic potential.54 The encouraging efficacy and safety profile 
shown in the present study further supports the use of this PB platform for ultimate 
clinical applications. Liu and colleagues have recently developed and validated an 
image-guided and computerized hydrodynamic gene delivery technique for hepatic 
gene delivery using large animal models.55 This improved method enables relatively 
efficient gene delivery by localized hydrodynamic liver delivery under controlled 
conditions, hereby minimizing liver damage compared to conventional hydrodynamic 
transfection methods. The efficacy and safety of this approach would need to be 
tested in canine hemophilia models.  Ultimately, nanoparticle transfection technology 
could be used as an alternative to overcome some of the limitations of naked DNA 
hydrodynamic transfection, including TLR-mediated activation of the innate immune 
system.37 Future research is required to validate the safety and efficacy of the PB 
platform in pre-clinical large animal models. 
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MATERIALS AND METHODS 
See supplementary experimental procedures for more details.  
 
Constructs 
 
The mouse codon-optimized PB transposase (mPB) and hyperactive PB transposase 
(hyPB) were custom-synthesized and expressed from a cytomegalovirus promoter 
(Figs. 1a,b). An identical expression plasmid devoid of PB (‘empty’) was used as 
control (Fig. 1c). The terminal inverted repeats (IRs) of the transposon-containing 
plasmids (Fig. 1) corresponded to truncated wild-type IRs 56, 57 (IRwt), contained T53C 
and C136T point mutations (IRmut16) 18 or were further truncated (IRmicro).19 The IRmut16  
and IRmicro were selected since they increased transposition efficiency based on in 
vitro studies. Wild-type, codon-optimized or hyperfunctional human factor IX cDNA  
(Fig. 1) was  expressed from a chimeric liver-specific promoter that was composed of 
a liver-specific minimal transthyretin (TTRmin) promoter in conjunction with a potent 
hepatocyte-specific cis-regulatory module (designated as HS-CRM8).20-22 Similarly, 
the PB-FVIII (Fig. 1i) or PB-c-Myc transposon (Fig. 1j)  used the same promoter to 
express the B-domain deleted FVIII or  c-Myc, respectively. 
 
Animal experiments 
 
C57Bl/6JRj, SCID or FIX-deficient hemophilia B mice in a C57Bl/6 background 
were employed. All animal procedures were approved by the institutional animal 
ethics committees. Mice were transfected by hydrodynamic liver transfection. We 
collected whole blood (≈ 200μl) by phlebotomy of the retro-orbital plexus. The 
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citrated plasma was stored at -80°C. A tumor-prone hepatocellular carcinoma (HCC) 
mouse model was established by diethylnitrosamine (DEN) initiation.32 One month 
later, mice were hydrodynamically injected. Survival was monitored and HCC 
nodules were examined at 36 weeks.  hFIX antigen and antibody levels were 
determined by ELISA as described.24  FVIII antigen levels were determined by 
ELISA, as described.31 FIX activity was determined using a functional assay and 
phenotypic correction was assessed in hemophilic mice using a tail-clip assay. 
Transposon copy number and transgene mRNA expression was determined by 
quantitative PCR and reverse transcriptase PCR, respectively.  
 
Statistics 
 
Data were analyzed using GraphPad software. Statistical analyses were performed 
using a two-tailed unpaired Student’s t-test. Results were presented as mean ± 
standard error of the mean. n.s. indicates not significant, *: p < 0.05, **: p < 0.01, 
***: p < 0.001. 
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FIG. LEGENDS 
 
Fig. 1. Schematic representation of PB transposon and transposase constructs. 
(a) Transposase constructs encoding for the native PB transposase mouse codon-
optimized (mPB) driven by the CMV promoter cloned upstream of a β-globin intron 
(βGI). (b) The hyperactive PB transposase mouse codon-optimized (hyPB). The 
hyperactivating mutations are indicated. (c) The empty control plasmid contains a 
multiple cloning site (MCS) between the promotor and polyadenylation signal. (d) 
The PB-hFIXIA transposon is flanked by wild-type inverted repeats (IRwt) and 
contains the wild-type hFIX cDNA harboring the truncated 1.4 kb hFIX intron A 
(intron IA) between the first hFIX exon (exon 1) and the following exons (exons 2-8). 
The hFIXIA minigene is driven by a chimeric promoter composed of the transthyretin 
minimal promoter (TTRmin) coupled to a hepatocyte-specific cis-regulatory module 
(designated as HS-CRM8) (e) In the PB-hFIXco transposon, the hFIXIA minigene 
was replaced by the synthetic codon-optimized hFIX (hFIXco) including a partial 3’ 
untranslated region. In addition, the minute virus of mice small intron (MVM) was 
introduced downstream of the chimeric HS-CRM8/TTRmin promoter. The PB 
transposons were flanked by three different inverted repeats: (e) wild-type minimal 
inverted repeats (IRwt) (PB-hFIXco/IRwt); (f) truncated “micro” inverted repeats 
(IRmicro) (PB-hFIXco/IRmicro) and (g) minimal mutant containing the T53C-C136T 
point mutations (IRmut16) (PB-hFIXco/IR mut16) (h) The PB-hFIXco-R338L/IRmicro 
transposon is flanked by IRmicro and contains a codon-optimized hFIX sequence with 
an R338L substitution. (i) The PB-hFVIIIΔBco/IRmicro contains a codon-optimized 
B-domain deleted FVIII sequence (hFVIIIΔBco) driven by the chimeric HS-
CRM8/TTRmin promoter coupled to a minute virus of mice small intron (MVM). (l)  
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PB-c-Myc is flanked by the IRw and contains the c-Myc oncogene under the control of 
the liver specific chimeric promoter. All the PB transposons were flanked with loxP 
sites (loxP) and contain the bovine growth hormone polyadenylation signal (bGHpA). 
 
Fig. 2. PB provides long-lasting therapeutic hFIX expression levels and 
phenotypic correction in hemophilia B mice 
 
Hemophilia B mice were hydrodynamically transfected with equimolar amounts (10 
μg) of PB-hFIXA (a) or PB-hFIXco (b) transposon plasmids  flanked by IRwt in 
conjunction with an equimolar amount (2 μg) of mPB-encoding plasmid (+ mPB) 
(full lines) or an empty control plasmid (+ empty) that does not contain any 
transposase gene (dashed lines). hFIX antigen expression (black squares) and FIX 
activity (grey squares) were measured on plasma samples collected at the indicated 
times by ELISA and a functional hFIX activity assay, respectively (a-b). Transposon 
copies per diploid genome (c) hFIX mRNA levels relative to FIXIA mRNA levels 
were determined on liver biopsies 12 months post-transfection (d). Results were 
presented as mean ± standard error of the mean. n.s. indicates not significant, *: p < 
0.05, **: p < 0.01, ***: p < 0.001 (n = 3 mice/group). 
 
Fig. 3. Increased therapeutic efficiency using the hyperactive PB platform 
CB17/IcrTac/Prkdcscid mice were hydrodynamically transfected with 500 ng (a, c, e) 
or 50 ng (b, d, f) of PB-hFIXco (a-f), PB-hFIXco/IRmicro (c, d; triangle) or PB-
hFIXco/IR mut16 (e, f; triangle) transposon plasmids along with 1000 ng (a, c) or 100 
ng (b, d) mPB (triangle a, b) or  hyPB-expressing plasmid (square a, b) or empty 
control plasmid (hatched lines). hFIX expression was measured on plasma samples 
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collected at the indicated times by a specific ELISA assay.  Results were presented as 
mean ± standard error of the mean. n.s. indicates not significant, *: p < 0.05, **: p < 
0.01, ***: p < 0.001 (n = 3 mice/group). 
 
Fig. 4. Enhancing PB performance  for hemophilia A and B 
 
Hemophilia B mice were hydrodynamically cotransfected with 500 ng (a) or 50 ng  
(b) of PB-hFIXco-R338L/IRmicro transposon with 1000 ng (a) or 100 ng (b) of hyPB-
expressing plasmid or an equimolar empty control plasmid (hatched lines). hFIX 
antigen  levels (black) and FIX activity (grey) were measured on plasma samples 
collected at the indicated times by a specific ELISA and a functional FIX assay, 
respectively (a, b, c). (c) Comparison of the original PB transposon system (PB-
hFIXIA + mPB) versus the improved PB platform (PB-hFIXco + hyPB; PB-hFIXco-
R338L/IRmicro + hyPB) in hemophilic mice using either 500 or 50 ng PB transposon 
(PB-hFIXIA, PB-hFIXco or  PB-hFIXco-R338L/IRmicro ) and 1000 ng or 500 ng PB 
transposase, respectively  (mPB or hyPB, as indicated).  A ratio of 1:2 
transposon/transposase was maintained.  (d) Three months after transfection with PB 
transposons  mice were subjected to immunization with recombinant  hFIX antigen 
and adjuvant as indicated (a,b). Anti-hFIX specific antibodies were measured by 
ELISA at week 2 (black) and week 4 (grey) post-immunization (p.i). PBS-injected 
hemophilia B mice that were immunized with recombinant hFIX and adjuvant were 
used as positive control. (e) Tail-clipping assay on hemophilia B mice treated with the 
indicated transposon constructs and doses (black bars). Blood loss was determined by 
measuring the absorbance at 575 nm of hemoglobin content in the saline solution in 
which the tail was placed. Wild-type and untreated hemophilia B (Hemo B) mice 
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were used as controls. (f) Transposon copies per diploid genome were determined on 
liver biopsies 6 months post-transfection. (g) FVIII antigen level in 
CB17/IcrTac/Prkdcscid mice hydrodynamically transfected with 500 ng PB-
hFVIIIΔBco/IRmicro transposon plasmids along with 1000 ng hyPB-expressing plasmid 
or an equimolar empty control plasmid (hatched lines). Physiologic hFVIII 
concentration (100% = 200 ng/ml) is indicated. hFVIII antigen levels were detected 
by ELISA. Results were presented as mean ± standard error of the mean. n.s. 
indicates not significant, *: p < 0.05, **: p < 0.01, ***: p < 0.001 (n = 3 mice/group)   
 
Fig. 5. Safety assessment in a tumor-prone hepatocellular carcinoma model  
(a) Diagram showing the timeline and experimental procedure. C57BL/6 male mice 
were subjected to a pre-weaning protocol of diethylnitrosamine (DEN) initiation. 
DEN (12.5 mg/kg) was injected intraperitoneally (i.p) in 14-days-old-mice. 4-weeks 
later, mice were hydrodynamically transfected with 10 μg PB-hFIXIA or 500 ng PB-
hFIXco transposons and 2 μg of mPB-encoding plasmid. hFIX expression was 
measured on plasma samples collected at different time points (bleedings) by ELISA. 
As controls, mice received PBS injection or a PB-c-Myc transposon (10 μg) 2 μg of 
mPB-encoding plasmid. Tumor burden was assessed 36-weeks post-DEN initiation. 
(b) Representative images showing the macroscopic liver appearance 36-weeks post-
DEN initiation in mice that received DEN only or DEN in combination with 
hydrodynamic injection (HDI). Liver nodules were counted for each group. (c) 
Representative picture showing the macroscopic tumor burden associated with PB 
mediated c-Myc expression and Kaplan-Meier survival curve of PB-c-Myc transposon 
and PBS-injected mice (c-Myc, n=9, median survival 157 days). (d) Transposon copy 
number quantification from genomic DNA isolated from normal liver biopsy 
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(hFIXIA, n=15; hFIXco, n=17; c-Myc, n=9) and HCC nodules (hFIXIA n=30 hFIXco 
n=34 and c-Myc n=18.) Results are presented as mean ± standard error of the mean. 
n.s. indicates not significant, *: p < 0.05, **: p < 0.01, ***: p < 0.001. 
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Table 1: Variants related differences in hepatocyte transduction efficiency, hFIX protein yield and 
activity per injected dose in piggyBac treated hemophilis B mice  
 
Treatment Injected dose μg 
(Transposon:Transposase) 
hFIX levels 
(ng/ml) 
hFIX activity 
(% normal) 
DNA copy number 
per diploid 
genome 
     
hFIXIA/IRwt + mPB   10:2 1168 ± 218 32 ± 6% 0.57 ± 0.09 
     
hFIXIA/IRwt + mPB   0.5:1 198 ± 90 2.9 ± 0.9% 0.11 ± 0.01 
     
hFIXIA/IRwt + mPB   0.05:0.1 n.d. n.d. 0.02 ± 0.005
     
 
hFIXco/IRwt + mPB 
 
10:2
 
13290 ± 990
 
313 ± 7% 
 
0.52 ± 0.03
     
hFIXco/IRmicro + hyPB 0.5:1 15456 ± 3042 356 ± 71% 0.35 ± 0.07
     
hFIXco-R338L/IRmicro + hyPB 0.5:1 9178 ± 1424 1205 ± 169% 0.34 ± 0.04
     
hFIXco-R338L/IRmicro + hyPB 0.05:0.1 1511 ± 602 194 ± 38% 0.08 ± 0.007
     
Hemophilia B mice were hydrodynamically injected with different hFIX transposons and transposase variants. Dose related 
hepatocyte transduction efficiency and protein yield for each tested variant is represented.  hFIXIA/IRwt, wild-type hFIX cDNA 
surrounded by the wild-type  inverted repeats;  hFIXco/IRwt,, synthetic codon-optimized hFIX sequence  surrounded by the wild-
type  inverted repeats;  hFIXco/IRmicro , synthetic codon-optimized hFIX sequence  surrounded by the truncated inverted repeats; 
hFIXco-R338L/IRmicro, synthetic codon-optimized hFIX sequence containing the hyper-functional mutation (R338L);  mPB, 
codon-optimized piggyBac transposase; hyPB, codon-optimized hyperactive piggyBac transposase.  
 
